Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis

Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01799824

Enrollment

Registered

2013-02-27

Start date

2013-02-28

Completion date

2013-07-31

Last updated

2013-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Axillary Hyperhidrosis

Brief summary

The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.

Interventions

BIOLOGICALANT-1403

BIOLOGICALplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* ages 18 - 70 years of age * diagnosis of moderate to severe primary axillary hyperhidrosis * ≥50 mg of sweat production/axilla in 5 minutes as measured gravimetrically * HDSS score of ≥3

Exclusion criteria

* diagnosis of secondary hyperhidrosis * skin affliction in the axilla requiring medical treatment * 20% aluminum hydrochloride, e.g. Drysol®, in 2 weeks prior of Baseline * oral anticholinergic treatment * botulinum toxin treatment in the prior 9 months * history of surgery for axillary hyperhidrosis * present or history of neuromuscular disease * female subjects who are pregnant or are nursing a child

Design outcomes

Primary

Measure	Time frame
HDSS	Week 8

Secondary

Measure	Time frame
GSP	Week 8

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026